MoonLake Immunotherapeutics (MLTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.06B
Last updated: Nov 17, 2026 at 4:24 PM ET
MoonLake Immunotherapeutics (MLTX) Statistics
MoonLake Immunotherapeutics (MLTX) has a market cap of $1.06B and an enterprise value of $784.14M. Its share count is up 34.73% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 26.29% below the market cap, as cash exceeds debt.
| Market Cap | $1.06B |
|---|---|
| Enterprise Value | $784.14M |
| Latest price (Nov 17, 2026) | $11.25 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 11.90% over 52 weeks and trades 4.17% below its 50-day average.
| Beta (1Y) | 1.62 |
|---|---|
| 52-Week Change | -11.90% |
| 1-Month Change | +15.38% |
| 3-Month Change | -32.80% |
| 6-Month Change | -31.28% |
| 5-Year Change | +17.80% |
| Total Return (1Y) | -11.90% |
| Total Return (3Y CAGR) | -35.91% |
| Total Return (5Y CAGR) | +2.55% |
| Return vs SPY (1Y) | -27.60% |
| Max Drawdown (1Y) | -56.90% |
| Max Drawdown (3Y) | -90.22% |
| Sharpe Ratio (1Y) | -0.25 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $11.74 |
| 200-Day Average | $16.22 |
| 52-Week Range | $9.46 to $23.29 |
| RSI (14 Days) | 44.8 |
| Average Volume (20 Days) | 1.66M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.13x current liabilities, and total debt is 0.26x shareholder equity.
| Current Ratio | 9.13x |
|---|---|
| Quick Ratio | 9.13x |
| Debt / Equity | 0.26x |
| Interest Coverage | -27.53x |
Returns and Efficiency
Return on invested capital is -54.59% over the last 12 months, against a 5-year average of -58.76%.
| Return on Equity (ROE) | -71.82% |
|---|---|
| Return on Assets (ROA) | -50.69% |
| Return on Invested Capital (ROIC) | -54.59% |
| Return on Capital Employed (ROCE) | -54.52% |
| ROA (5Y Average) | -43.77% |
| ROIC (5Y Average) | -58.76% |
Scores
MLTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$751.00K |
| Operating Income | -$276.75M |
| Pretax Income | -$272.48M |
| Net Income | -$274.07M |
| EBITDA | -$259.54M |
| EBIT | -$262.93M |
| Reported EPS (TTM) | -$3.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 70.58% of the $540.72M in total assets.
| Cash and Equivalents | $379.70M |
|---|---|
| Total Debt | $100.01M |
| Net Cash | $279.69M |
| Net Cash Per Share | $3.28 |
| Working Capital | $474.91M |
| Shareholder Equity | $381.63M |
| Book Value Per Share | $4.47 |
| Total Assets | $540.72M |
| Total Liabilities | $159.09M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$244.04M |
|---|---|
| FCF Per Share | -$2.87 |
| Depreciation and Amortization | $3.40M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -24.44% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -24.44% |
Dividends and Yields
MLTX does not pay a dividend.
| Buyback Yield | -15.74% |
|---|---|
| Shareholder Yield | -15.74% |
Peer Position
Against 7 similar companies, MLTX has the 7th highest ROIC.
ROICPeer median -14.91%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -8.87%
| ROIC | -54.59% vs -14.91% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -8.87% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MLTX
What is MLTX's market cap?
MoonLake Immunotherapeutics has a market cap of $1.06B. Its enterprise value, which adds debt and subtracts cash, is $784.14M.
How many shares of MLTX are outstanding?
MoonLake Immunotherapeutics has 85.38M shares outstanding. The count is up 34.73% from a year earlier.
Does MLTX pay a dividend?
No. MoonLake Immunotherapeutics does not pay a dividend.
How much debt does MLTX have?
MoonLake Immunotherapeutics has $100.01M of total debt and $379.70M of cash and equivalents, a net cash position of $279.69M.
MLTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors